Homemarket Newsstocks News

Zydus Lifesciences gets USFDA approval for injection used in treating ulcers

Zydus Lifesciences gets USFDA approval for injection used in treating ulcers

Zydus Lifesciences gets USFDA approval for injection used in treating ulcers
Read Time
1 Min(s) Read
Profile image

By CNBCTV18.com Nov 23, 2022 4:43:37 PM IST (Published)

The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara, Gujarat.

wealth-desk wealth-desk

Buy / Sell Zydus Life share

Recommended Articles

View All

Zydus Lifesciences Ltd. has received final approval from the United States Food and Drug Administration (USFDA) to market famotidine injection USP, 40 mg/4 mL (10 mg/mL) and 200 mg/20 mL (10 mg/mL) multiple-dose vials.
Famotidine Injection is used to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed.
This medication is also used to treat certain stomach and throat (esophagus) problems such as erosive esophagitis, gastroesophageal reflux disease-GERD, and Zollinger-Ellison syndrome.
Famotidine injection had annual sales of $1.9 million in the United States, according to IQVIA data, for the 12-month period that ended in September 2022.
The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara, Gujarat.
Zydus Lifesciences reported a net profit drop of 82 percent during the September quarter to Rs 522.5 crore, while revenue increased to Rs 4,134.7 crore from Rs 3,759.8 crore during the same period last year.
Shares of Zydus Lifesciences ended 0.3 percent higher at Rs 393.55.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!

Most Read

Market Movers

View All
Top GainersTop Losers
CurrencyCommodities
CompanyPriceChng%Chng